GlassScriptPhysician profile
Albert J Sharf
NPI 1649349820
$51,943.18
in general payments reported to CMS, 2019-2025
50 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,360 · 2020: $2,602 · 2021: $6,335 · 2022: $13K · 2023: $16K · 2024: $7,681 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $8,564 · Education: $164 · Travel and Lodging: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,750.00 |
| Food and Beverage | $8,564.08 |
| Education | $164.00 |
| Travel and Lodging | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28,079.50 | 2019-2025 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,903.72 | 2019-2025 | Lifevest |
| Pfizer INC. | $1,437.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,343.27 | 2019-2025 | |
| Biotronik INC. | $1,104.98 | 2019-2024 | Biomonitor, Acticor 7 Vr-T Dx, Rivacor 7 Dr-T |
| Astrazeneca Pharmaceuticals LP | $1,024.54 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $963.17 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $956.54 | 2021-2025 | |
| Amgen INC. | $892.09 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $726.65 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $567.70 | 2021-2025 | Verquvo, Lagevrio |
| Novo Nordisk INC | $555.85 | 2021-2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $511.97 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $402.27 | 2022-2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $373.51 | 2019-2025 | Evkeeza, Praluent |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $345.49 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $319.69 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $238.19 | 2021-2023 | Arcalyst |
| Astellas Pharma US INC | $207.38 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $163.41 | 2019-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $158.68 | 2021-2024 | Camzyos, Eliquis |
| Lilly USA, LLC | $143.17 | 2019-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $140.78 | 2019-2022 | |
| Medtronic, INC. | $133.56 | 2021-2023 | Micra |
| Braemar Manufacturing, LLC | $132.06 | 2019 | |
| Abiomed | $126.10 | 2024-2025 | Impella |
| Gilead Sciences, INC. | $125.82 | 2019 | |
| Abbott Laboratories | $104.41 | 2019-2023 | Mitraclip |
| Inspire Medical Systems, INC. | $91.35 | 2025 | Inspire |
| Heartflow, INC. | $84.34 | 2024 | |
| Sanofi-Aventis U.S. LLC | $79.11 | 2019-2021 | |
| Medtronic Vascular, INC. | $70.90 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $60.15 | 2024 | Arcalyst |
| Infobionic, INC | $55.36 | 2025 | Mome Device |
| Daiichi Sankyo INC. | $46.41 | 2022-2023 | Injectafer |
| Baxter Healthcare | $46.27 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $29.93 | 2024 | Amvuttra |
| Sobi, INC | $26.77 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $26.69 | 2024 | Rhythm Express |
| Hikma Pharmaceuticals USA | $19.36 | 2023 | Mitigare |
| Edwards Lifesciences Corporation | $17.49 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $17.22 | 2021 | |
| Vifor Pharma, INC. | $17.00 | 2019 | |
| Ionis Pharmaceuticals, INC. | $16.78 | 2025 | Tryngolza |
| Glaxosmithkline, LLC. | $16.66 | 2025 | Shingrix |
| Esperion Therapeutics, INC. | $16.43 | 2025 | Nexletol, Nexlizet |
| Atricure, INC. | $11.89 | 2019 | |
| W. L. Gore & Associates, INC. | $11.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Sharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.